Kromek Group plc ( ($GB:KMK) ) has issued an announcement.
Kromek Group plc has entered into multi-year agreements with Siemens Healthineers for the licensing and production of CZT-based detectors, expected to generate $37.5 million over four years. The agreements include transferring production assets and supplying detector tiles, positioning Kromek for profitability in FY 2025, with significant revenue and profit growth, and enhanced capabilities in the advanced imaging market.
More about Kromek Group plc
Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions, focusing on advanced imaging and CBRN detection segments. Based in County Durham, UK, with operations in the UK and US, Kromek specializes in manufacturing detector components using its core cadmium zinc telluride (CZT) platform, serving medical, security, and industrial markets. The company also provides nuclear radiation detection solutions for homeland defense and security, and is developing bio-security solutions to detect airborne pathogens.
YTD Price Performance: 6.00%
Average Trading Volume: 1,206,073
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £34M
See more insights into KMK stock on TipRanks’ Stock Analysis page.
